TITLE

Effect of Gemfibrozil on Serum Lipids in Man

AUTHOR(S)
Fenderson, Ralph W.; Deutsch, Stanley; Menachemi, Eli; Chin, Bruce; Samuel, Paul
PUB. DATE
September 1982
SOURCE
Angiology;Sep1982, Vol. 33 Issue 9, p581
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The effect of gemfibrozil, a new lipid-lowering agent, was studied in 22 patients. Each patient served as his own control in a double blind study. The administration of gemfibrozil, for a period of 24 months, 1200 mg daily, reduced mean serum triglyceride levels by 45.6% (p<0.001) and mean serum cholesterol levels by 8.3% (p<0.001). Mean serum HDL cholesterol was increased by 32.3% (p<.0001) and mean serum LDL cholesterol levels were decreased by 11.4% (p<0.01). Mean serum VLDL cholesterol was decreased by 45.9% (p<0.001). A 3-hour glucose-tolerance test was done in each patient during a placebo-control period and during the administration of gemfibrozil. Mean plasma glucose was moderately increased during the administration of gemfibrozil at all points on the glucose tolerance curve, and to levels of significance at one (p<0.05) and two hours (p<0.02). There was no effect of the drug on serum immunoreactive insulin. No subjective side effects were apparent.
ACCESSION #
16525308

 

Related Articles

  • Vildagliptin was noninferior to rosiglitazone for glycemic control in type 2 diabetes but caused less weight gain: COMMENTARY. Montori, Victor M. // ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p74 

    The author comments on a study on the relative efficacy and tolerability of vildagliptin and rosiglitazone in patients with type 2 diabetes. He asserted that the measurement of hemoglobin level in patients with type 2 diabetes may not capture all the benefits. Thus, large trials of sufficient...

  • Vildagliptin was noninferior to rosiglitazone for glycemic control in type 2 diabetes but caused less weight gain. Rosenstock, J.; Baron, M. A.; Dejager, S.; Mills, D.; Schweizer, A. // ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p74 

    The article presents a study on the relative efficacy and tolerability of vildagliptin and rosiglitazone in patients with type 2 diabetes. Results revealed that vildagliptin lessens the fasting plasma lipid levels more than rosiglitazone. It is also stated that vildagliptn does not reduce the...

  • One thing leads to another. Hirsch, Jules // Journal of Clinical Investigation;Oct2004, Vol. 114 Issue 8, p1040 

    In 1956, the JCI published an article by Vincent Dole on a method for titrating plasma fatty adds that uncovered the importance of fatty adds as a substrate for glucose metabolism. When asked to prepare a historical perspective on this very popular paper, I paid Dole a visit and we reminisced....

  • Insulin and glucose metabolism in renal insufficiency. Reaven, Gerald M.; Weisinger, Jose R.; Swenson, Robert S. // Kidney International Supplement;Oct1974, Issue 1, pS-63 

    The article presents information related to insulin and glucose metabolism in renal insufficiency. Carbohydrate intolerance was first recognized in uremic subjects in the early 1900's and these original observations have been repeatedly confirmed. Although this abnormality appears to exist to...

  • The association of hs-CRP with fasting and postprandial plasma lipids in patients with type 2 diabetes is disrupted by dietary monounsaturated fatty acids. Bozzetto, L.; De Natale, C.; Di Capua, L.; Della Corte, G.; Patti, L.; Maione, S.; Riccardi, G.; Rivellese, A.; Annuzzi, G. // Acta Diabetologica;Apr2013, Vol. 50 Issue 2, p273 

    The aim of the study was to evaluate whether two dietary approaches recommended for diabetes mellitus and cardiovascular prevention-high-MUFA or complex carbohydrates/fiber-differently influence inflammation. A 4-week crossover study in 12 individuals with type 2 diabetes was performed. Fasting...

  • Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung cancer patients. Ravipati, Srinivasarao; Baldwin, David; Barr, Helen; Fogarty, Andrew; Barrett, David // Metabolomics;Dec2015, Vol. 11 Issue 6, p1600 

    There is a clinical need for reliable biomarkers for lung cancer that permit early diagnosis of the disease and provide prediction of histological phenotype. A prospective study design was used with a study population of patients with suspected lung cancer. Blood samples were collected from 17...

  • Relationship between cardiovascular risk factors and blood adiponectin in diabetic males. Izadi, M.; Zarifian, A.; Eghdami, A.; Khorshidi, D.; Doeli, H. // Iranian South Medical Journal;2012, Vol. 15 Issue 2, p101 

    Background: Obesity-related disorders characterized by insulin resistance such as metabolic syndrome, hypertension, coronary artery disease and type 2 diabetes are associated with decreased adiponectin levels. The purpose of the present study was to determine association of lipid profile and...

  • Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus. Brøns, C.; Spohr, C.; Storgaard, H.; Dyerberg, J.; Vaag, A. // European Journal of Clinical Nutrition;Sep2004, Vol. 58 Issue 9, p1239 

    BACKGROUND:: The prevalence of type 2 diabetes mellitus (T2DM) is increasing with an epidemic growth rate. Animal studies with taurine supplementation have shown increased insulin secretion and action, suggesting that taurine supplementation may have a potential to prevent T2DM. OBJECTIVE:: To...

  • Relevance of Mediterranean diet and glucose metabolism for nephrolithiasis in obese subjects. Soldati, Laura; Bertoli, Simona; Terranegra, Annalisa; Brasacchio, Caterina; Mingione, Alessandra; Dogliotti, Elena; Raspini, Benedetta; Leone, Alessandro; Frau, Francesca; Vignati, Laila; Spadafranca, Angela; Vezzoli, Giuseppe; Cusi, Daniele; Battezzati, Alberto // Journal of Translational Medicine;2014, Vol. 12 Issue 1, p1 

    Background Nephrolithiasis is more frequent and severe in obese patients from different western nations. This may be supported by higher calcium, urate, oxalate excretion in obese stone formers. Except these parameters, clinical characteristics of obese stone formers were not extensively...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics